DRUG NAME: Telmisartan
Therapeutic Class: Antihypertensive
Subclass: Angiotensin II Receptor Blocker (ARB)
Speciality: Cardiology
Schedule (India): Schedule H
Route(s): Oral
Formulations Available in India:
• Tablets: 20 mg, 40 mg, 80 mg
Primary Indications (Approved / Standard in India)
1. Hypertension
• Telmisartan has the longest half-life among ARBs (~24 hours), providing consistent 24-hour blood pressure control with true once-daily dosing. High trough-to-peak ratio ensures sustained overnight and early-morning blood pressure coverage — clinically relevant for reducing morning surge-related cardiovascular events.
• Can be taken with or without food; absorption is not significantly affected by meals.
• Can be used as monotherapy or in combination with other antihypertensives. Commonly combined with hydrochlorothiazide, chlorthalidone, or amlodipine — widely available as fixed-dose combinations (FDCs) in India.
• If blood pressure is not controlled on telmisartan 80 mg monotherapy, addition of a low-dose thiazide/thiazide-like diuretic or calcium channel blocker is preferred over exceeding the maximum dose.
• First-dose hypotension risk is lower than with ACE inhibitors but still relevant in volume-depleted or salt-depleted patients — correct volume status or reduce diuretic dose before starting.
• Listed on NLEM India 2022 (40 mg tablet) — preferred ARB for public health use in India.
2. Cardiovascular Risk Reduction (in patients at high vascular risk who are intolerant to ACE inhibitors)
• Based on the ONTARGET trial (2008): telmisartan 80 mg was non-inferior to ramipril 10 mg for the composite of cardiovascular death, myocardial infarction, stroke, and hospitalisation for heart failure in patients with vascular disease or high-risk diabetes.
• Primary role is in patients intolerant to ACE inhibitors (typically due to persistent dry cough) who require RAAS blockade for cardiovascular protection.
• The TRANSCEND trial further supported telmisartan in ACE inhibitor-intolerant patients, showing reduction in composite cardiovascular endpoints (secondary analysis).
• Do not combine telmisartan with an ACE inhibitor for dual RAAS blockade — the ONTARGET combination arm showed increased renal adverse events without additional cardiovascular benefit.
• Applicable in patients aged ≥55 years with established atherosclerotic cardiovascular disease (coronary artery disease, peripheral arterial disease, cerebrovascular disease) or type 2 diabetes with end-organ damage.
Secondary Indications — only Adults (Off-label, if any)
1. Diabetic Nephropathy / Proteinuric Chronic Kidney Disease — OFF-LABEL for telmisartan specifically; class effect of ARBs
• Dose: 40–80 mg once daily
• Duration: Long-term
• Specialist only: Co-management with nephrologist recommended when eGFR <30 mL/min/1.73 m²
• Evidence basis: DETAIL trial (telmisartan vs enalapril in type 2 diabetic nephropathy) demonstrated equivalent renoprotection. The antiproteinuric effect of ARBs is well established (RENAAL and IDNT trials were with losartan and irbesartan respectively, but class effect is accepted in Indian nephrology practice). Telmisartan is commonly used for this purpose in Indian clinical practice.
• Clinical notes: Monitor serum creatinine and potassium within 1–2 weeks of initiation. Accept up to 30% rise in creatinine from baseline. Higher doses (80 mg) provide greater antiproteinuric effect independent of blood pressure reduction.
2. Heart Failure with Reduced Ejection Fraction (HFrEF) — OFF-LABEL; Specialist only
• Dose: 40–80 mg once daily
• Duration: Long-term
• Specialist only: Use only when ACE inhibitors and preferred ARBs (valsartan, candesartan) are not available or tolerated
• Evidence basis: Limited direct evidence for telmisartan in HFrEF. Valsartan (Val-HeFT) and candesartan (CHARM trials) have stronger outcome data in heart failure. Telmisartan may be considered as a class substitute under specialist supervision when preferred agents are unavailable. Used in some Indian hospital protocols as an alternative ARB for heart failure.
Primary Indications (Approved / Standard in India)
Not applicable. Safety and efficacy of telmisartan have not been established in the paediatric population in India.
Secondary Indications — Paediatric doses (Off-label, if any)
Not applicable.
Clear statement: Not recommended below 18 years of age except under specialist supervision (paediatric cardiologist or nephrologist). No validated Indian paediatric dosing data exist for telmisartan. If an ARB is required in children, losartan is the preferred agent with established paediatric dosing data (IAP guidelines).
• Telmisartan is predominantly eliminated via biliary/faecal route (>97%); renal excretion is minimal (<1%). Therefore, accumulation in renal impairment is not a pharmacokinetic concern, but pharmacodynamic effects (hyperkalemia, worsening renal function) remain relevant.
• Monitor serum creatinine and potassium within 1–2 weeks of initiation and after each dose change. Accept up to 30% rise in creatinine from baseline; if greater, reduce dose or discontinue.
• Mild impairment: No dose adjustment required.
• Moderate impairment: Maximum dose should not exceed 40 mg once daily. Telmisartan is extensively metabolised by glucuronidation in the liver and almost entirely excreted via bile. Hepatic impairment significantly increases plasma concentrations (approximately 3–4 fold increase in AUC reported in moderate impairment). Use with close monitoring of hepatic function and blood pressure.
• Severe impairment: Contraindicated. Marked increase in drug exposure and biliary excretion impairment makes use unsafe. Includes decompensated cirrhosis and cholestatic disorders.
• Biliary obstruction: Contraindicated — telmisartan elimination is almost exclusively biliary; obstruction will cause severe drug accumulation.
• Known hypersensitivity to telmisartan or any excipient in the formulation
• Pregnancy (second and third trimesters) — established fetotoxicity (renal dysgenesis, oligohydramnios, skull ossification defects, neonatal renal failure, and death)
• Biliary obstruction or severe cholestatic disorders — telmisartan is almost exclusively eliminated via the biliary route
• Severe hepatic impairment (Child-Pugh C)
• Concurrent use with aliskiren in patients with diabetes mellitus or renal impairment (eGFR <60 mL/min/1.73 m²) — dual RAAS blockade increases risk of hypotension, hyperkalemia, and renal failure
• Concurrent use with sacubitril/valsartan — risk of angioedema; allow 36-hour washout if switching from sacubitril/valsartan to telmisartan (though this combination is less commonly encountered than with ACE inhibitors)
• Hereditary fructose intolerance — some telmisartan formulations contain sorbitol as excipient
• Volume-depleted or salt-depleted patients (e.g., on high-dose diuretics, vomiting, diarrhoea, restricted salt intake): Risk of symptomatic hypotension — correct volume status before initiation or start at lowest dose (20 mg) under observation
• Renal artery stenosis (bilateral, or unilateral in a solitary kidney): Risk of acute renal failure — monitor renal function closely if ARB is considered essential
• Pre-existing renal impairment: Pharmacodynamic risk of hyperkalemia and worsening renal function despite minimal renal drug excretion
• Aortic stenosis, mitral stenosis, or hypertrophic obstructive cardiomyopathy: Increased risk of critical hypotension
• Patients on concomitant potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes: Risk of hyperkalemia
• Primary hyperaldosteronism: ARBs are generally ineffective; specialist evaluation needed
• Major surgery or general anaesthesia: Enhanced hypotensive effect with anaesthetic agents
• Patients with ischaemic heart disease or cerebrovascular disease: Excessive blood pressure reduction may precipitate ischaemic events
• Recommended starting dose: 20–40 mg once daily (same range as younger adults; no pharmacokinetic dose adjustment required as telmisartan clearance is not significantly age-dependent)
• Titration: May need slower dose adjustment (4-week intervals); target blood pressure goals may be less aggressive in frail elderly
• Extra risks:
- Postural hypotension and resultant falls/fractures — particularly in patients on multiple antihypertensives or diuretics
- Age-related reduction in renal functional reserve — always check baseline eGFR and electrolytes; serum creatinine alone may underestimate renal impairment due to reduced muscle mass
- Greater susceptibility to hyperkalemia (reduced renal potassium excretion, polypharmacy)
- Assess for undiagnosed renovascular disease (atherosclerotic renal artery stenosis) before initiation, especially in patients with generalised atherosclerosis or refractory hypertension
• Monitor serum creatinine and potassium within 1–2 weeks of initiation and after each dose change
• Dizziness and light-headedness — related to blood pressure reduction, more common early in treatment
• Upper respiratory tract infections (nasopharyngitis, sinusitis)
• Back pain and myalgia
• Diarrhoea
• Fatigue
• Hypotension — particularly in volume-depleted patients
• Notably absent: dry cough. Unlike ACE inhibitors, ARBs do not inhibit bradykinin degradation and therefore carry a negligible risk of cough. This is the principal reason for switching from ACE inhibitors to ARBs in clinical practice.
• Angioedema: Rare with ARBs but reported. Requires immediate discontinuation and emergency management. Risk is lower than with ACE inhibitors but not zero. Exercise caution in patients with a history of ACE inhibitor-induced angioedema — approximately 2–17% cross-reactivity risk. Do not re-challenge if angioedema occurs with telmisartan.
• Hyperkalemia: Especially in renal impairment, diabetes, or concurrent potassium-elevating agents. Can cause life-threatening cardiac arrhythmias.
• Acute renal failure: Particularly in bilateral renal artery stenosis, severe heart failure, or volume depletion.
• Severe hypotension: May cause syncope, stroke, or myocardial ischaemia in susceptible patients.
• Hepatotoxicity: Rare; cases of hepatocellular injury have been reported. Discontinue if marked elevation of hepatic enzymes or jaundice develops.
• Rhabdomyolysis: Very rare; reported in post-marketing surveillance. Monitor for unexplained muscle pain, tenderness, or weakness with elevated creatine kinase levels.
• Telma (Glenmark) — most widely prescribed brand in India
• Cresar (Cipla)
• Telmikind (Mankind)
• Telsar (Unichem)
• Telvas (Aristo)
FDCs widely available in India:
• Telmisartan + Hydrochlorothiazide (e.g., Telma-H, Cresar-H): 40/12.5 mg, 80/12.5 mg
• Telmisartan + Amlodipine (e.g., Telma-AM, Cresar Plus): 40/5 mg, 80/5 mg
• Telmisartan + Chlorthalidone (e.g., Telma-CT): 40/12.5 mg, 80/12.5 mg
• 20 mg tablet: ₹3–₹8 per tablet
• 40 mg tablet: ₹4–₹12 per tablet
• 80 mg tablet: ₹8–₹20 per tablet
• Telmisartan 40 mg is listed on NLEM India 2022 and is under NPPA price control — ceiling price applies to 40 mg tablets
• Government facility supply: Widely available through government procurement; telmisartan is one of the most commonly stocked ARBs in public health facilities in India
• Longest-acting ARB — true once-daily dosing: Telmisartan has a half-life of ~24 hours (longest among all ARBs), providing consistent 24-hour blood pressure control. It offers superior trough-to-peak ratio, making it particularly useful in patients with poor adherence to twice-daily regimens or those with early-morning blood pressure surge.
• ACE inhibitor cough — switch to telmisartan: The most common clinical scenario for initiating telmisartan in India is switching from an ACE inhibitor (enalapril, ramipril) due to persistent dry cough. No washout period is required — simply substitute at the next scheduled dose. ARBs do not cause cough because they do not affect bradykinin metabolism.
• Hepatic metabolism — unique among RAAS blockers: Unlike most other ARBs and ACE inhibitors, telmisartan is almost exclusively eliminated via biliary excretion (>97%). This means renal impairment has minimal impact on drug clearance, but hepatic impairment significantly increases drug exposure. Contraindicated in biliary obstruction and severe liver disease — a distinction from other ARBs.
• NLEM India listing and cost advantage: Telmisartan 40 mg is on the NLEM 2022, making it price-controlled and widely available. It is the preferred ARB in Indian public health programmes for hypertension management.
• Not a direct substitute in heart failure: For HFrEF, valsartan and candesartan have the strongest evidence among ARBs (Val-HeFT, CHARM trials). Telmisartan should be used for heart failure only when these preferred agents and ACE inhibitors are unavailable or not tolerated.
• PPAR-γ partial agonist activity: Telmisartan has unique partial PPAR-γ agonist properties, providing modest insulin-sensitising and metabolic benefits. This makes it a rational choice in hypertensive patients with metabolic syndrome or type 2 diabetes, though the clinical magnitude of this effect is modest compared to dedicated antidiabetic agents.
VERSION
RxIndia v0.1 — 01 Mar 2026
• CDSCO product inserts (Telmisartan)
• Indian Pharmacopoeia
• NLEM India 2022 (telmisartan 40 mg listed)
• API Textbook of Medicine
• AIIMS Treatment Guidelines
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics
• Harrison’s Principles of Internal Medicine
• ICMR Guidelines (hypertension management)
• ONTARGET Investigators. N Engl J Med 2008;358:1547–59 (cardiovascular risk reduction — primary evidence)
• TRANSCEND Investigators. Lancet 2008;372:1174–83 (ACE inhibitor-intolerant patients — supportive evidence)
• Barnett AH et al. (DETAIL trial) N Engl J Med 2004;351:1952–61 (telmisartan vs enalapril in diabetic nephropathy — off-label evidence basis)